Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 12.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 192,175 shares of the medical equipment provider's stock after selling 28,573 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned about 0.10% of Zimmer Biomet worth $20,745,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in ZBH. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet during the 3rd quarter valued at about $28,000. Bangor Savings Bank bought a new stake in shares of Zimmer Biomet during the third quarter worth $31,000. Family Firm Inc. bought a new position in Zimmer Biomet in the second quarter valued at $33,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Zimmer Biomet in the second quarter valued at $43,000. Finally, Ridgewood Investments LLC acquired a new stake in shares of Zimmer Biomet during the 2nd quarter worth about $43,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on ZBH shares. Canaccord Genuity Group decreased their target price on shares of Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, September 10th. JPMorgan Chase & Co. dropped their price target on shares of Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating on the stock in a research report on Monday, September 16th. Raymond James dropped their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating on the stock in a research report on Monday, October 14th. BTIG Research decreased their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating for the company in a research note on Thursday, October 3rd. Finally, UBS Group reduced their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating for the company in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and a consensus price target of $123.22.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH traded up $1.82 during trading on Friday, reaching $110.22. The stock had a trading volume of 2,015,059 shares, compared to its average volume of 1,734,120. The business has a fifty day moving average price of $106.79 and a 200-day moving average price of $109.78. The stock has a market cap of $21.94 billion, a PE ratio of 20.96, a PEG ratio of 1.99 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the business earned $1.65 EPS. The company's quarterly revenue was up 4.1% compared to the same quarter last year. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. Zimmer Biomet's payout ratio is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.